Pharma Mar Sau Stock Net Income
| PHMMF Stock | USD 86.26 0.00 0.00% |
Fundamental analysis of Pharma Mar allows traders to better anticipate movements in Pharma Mar's stock price by examining its financial health and performance throughout various phases of its business cycle.
Pharma |
Pharma Mar SAU Company Net Income Analysis
Pharma Mar's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pharma Mar Net Income | 92.86 M |
Most of Pharma Mar's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SAU is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Pharma Mar SAU reported net income of 92.86 M. This is 72.79% lower than that of the Healthcare sector and 32.57% higher than that of the Biotechnology industry. The net income for all United States stocks is 83.74% higher than that of the company.
Pharma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in net income category among its peers.
Pharma Fundamentals
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.12 B | |||
| Shares Outstanding | 18.09 M | |||
| Shares Owned By Insiders | 26.95 % | |||
| Shares Owned By Institutions | 10.48 % | |||
| Price To Earning | 7.38 X | |||
| Price To Book | 5.60 X | |||
| Price To Sales | 5.57 X | |||
| Revenue | 229.83 M | |||
| Gross Profit | 213.39 M | |||
| EBITDA | 104.08 M | |||
| Net Income | 92.86 M | |||
| Cash And Equivalents | 196.7 M | |||
| Cash Per Share | 10.92 X | |||
| Total Debt | 33.39 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 2.86 X | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.97 X | |||
| Number Of Employees | 477 | |||
| Beta | 0.12 | |||
| Market Capitalization | 1.26 B | |||
| Total Asset | 368.39 M | |||
| Retained Earnings | (17 M) | |||
| Working Capital | 32 M | |||
| Current Asset | 110 M | |||
| Current Liabilities | 78 M | |||
| Z Score | 22.2 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 368.39 M | |||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SAU's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SAU based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Pharma Pink Sheet
Pharma Mar financial ratios help investors to determine whether Pharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.